From 3
rd July 2020, an interim clinical commissioning policy has been put in place to define routine access to remdesivir in the treatment of COVID-19 across the UK.
Remdesivir
- Concentrate for solution for infusion 5mg/ml vials
- Powder for concentrate for solution for infusion vials 100mg
Notes
- Remdesivir is recommended as a treatment option for patients hospitalised with COVID-19 (adults and children aged 12 years and older) in accordance with the criteria set out in the updated policy
document (06 November 2020)
(see
interim
clinical commissioning policy
for more details). The commissioning policy has
been updated to reflect the more positive position on remdesivir supply into
the UK. The updated policy includes a clinical pathway and new criteria for
initiation of treatment, risk assessment, reassessment and review. Co-administration
of dexamethasone and hydrocortisone with remdesivir is included. The maximum
treatment course is 5 days in total (comprising a loading dose plus 4 further days
of maintenance treatment)
Last updated: 09-11-2020
Home >
Formulary >
Chapters >
5. Infections >
5.3 Antiviral drugs >
5.3.6 Other antiviral drugs
- First line
- Second line
- Specialist
- Hospital
